14.26
0.07 (0.46%)
| Previous Close | 14.19 |
| Open | 14.29 |
| Volume | 294,906 |
| Avg. Volume (3M) | 1,326,893 |
| Market Cap | 657,538,944 |
| Price / Earnings (TTM) | 10.64 |
| Price / Earnings (Forward) | 5.49 |
| Price / Sales | 1.41 |
| Price / Book | 1.16 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2024 - 4 Nov 2024 |
| Profit Margin | -13.06% |
| Operating Margin (TTM) | 13.02% |
| Diluted EPS (TTM) | -1.98 |
| Quarterly Revenue Growth (YOY) | 2.80% |
| Quarterly Earnings Growth (YOY) | -26.70% |
| Total Debt/Equity (MRQ) | 85.97% |
| Current Ratio (MRQ) | 2.25 |
| Operating Cash Flow (TTM) | 203.84 M |
| Levered Free Cash Flow (TTM) | 169.56 M |
| Return on Assets (TTM) | 4.17% |
| Return on Equity (TTM) | -11.48% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Pacira BioSciences, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.13 |
|
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 2.15% |
| % Held by Institutions | 114.51% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 39.00 (HC Wainwright & Co., 173.59%) | Buy |
| Median | 19.50 (36.79%) | |
| Low | 16.00 (RBC Capital, 12.24%) | Hold |
| Average | 23.50 (64.85%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 17.71 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Dec 2024 | 39.00 (173.59%) | Buy | 19.09 |
| Barclays | 12 Nov 2024 | 17.00 (19.26%) | Hold | 16.80 |
| Needham | 08 Nov 2024 | 22.00 (54.33%) | Buy | 17.24 |
| RBC Capital | 07 Nov 2024 | 16.00 (12.24%) | Hold | 17.70 |
| 04 Oct 2024 | 15.00 (5.23%) | Hold | 16.52 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |